疑难病杂志2024，Vol.23Issue(1)：46-51,6.DOI:10.3969/j.issn.1671-6450.2024.01.008
胃镜活检组织SF3B4及miR-96表达在胃癌病情及预后评估中的临床价值
The clinical value of SF3B4 and miR-96 expression in gastroscopy biopsy tissue in the evaluation of gastric cancer condition and prognosis
摘要
Abstract
Objective To analyze the clinical value of splicing factor3b subunit 4(SF3B4)and microRNA-96(miR-96)expression in gastric cancer disease and prognosis evaluation in endoscopic biopsy tissue.Methods Ninety-five gas-tric cancer patients diagnosed and treated in the General Surgery Department of Honghu People's Hospital in Hubei Prov-ince from January to December 2017 were selected as the gastric cancer group,and 60 patients with benign gastric diseases were selected as the non gastric cancer group.Real time fluorescence quantitative PCR(RT qPCR)was used to detect the expression of SF3B4 and miR-96 in tissues,and the differences in SF3B4 and miR-96 expression in different clinical and path-ological data were compared;The value of using ROC curve analysis to predict poor 1-year prognosis of gastric cancer using SF3B4 and miR-96;Multivariate logistic regression analysis of risk factors for death in gastric cancer patients;Kaplan Meier method was used to analyze the relationship between SF3B4,miR-96 expression and survival.Results The expres-sion of SF3B4 and miR-96 in tumor tissues of gastric cancer group was significantly higher than that in adjacent tissues and non gastric cancer group lesion tissues(F/P=516.766/<0.001,887.495/<0.001).The expression of SF3B4 and miR-96 in pa-tients with poorly differentiated gastric cancer,maximum tumor diameter≥5 cm,T3-4,lymph node metastasis,and cTNM staging Ⅲ-Ⅳ was significantly higher than that in patients with moderately well differentiated gastric cancer,maximum tumor diameter<5 cm,T1-2 Patients with no lymph node metastasis and cTNM stage Ⅰ-Ⅱ(SF3B4:t/P= 4.151/<0.001,5.695/<0.001,6.561/<0.001,7.943/<0.001,4.629/<0.001;miR-96:t/P=4.543/<0.001,3.692/<0.001,5.061/<0.001,5.842/<0.001,5.109/<0.001).The AUCof SF3B4,miR-96,and their combination for predicting poor1-year prognosis in gastric cancer were 0.785,0.779,and 0.952,respectively.The combined predictive efficacy of SF3B4,miR-96,and their combination was superior to their individual predictive efficacy(Z/P=3.451/0.017,3.565/0.014).Multivariate logistic regression analysis showed that SF3B4≥1.51,miR-96≥1.28,poorly differentiated tumor,maximum tumor diameter≥5 cm,depth of tumor infiltration T3-4,presence of lymph node metastasis,and cTNM stage Ⅲ-Ⅳ were independent risk factors for 1-year mortality in gastric cancer[OR(95％CI)=4.225(1.034-4.623),3.877(1.142-6.189),2.261(1.275-5.726),2.487(1.338-7.516),2.088(1.023-5.367)2.779(1.161-4.591),3.013(1.416-5.791)].Among 95 gastric cancer patients,36 survived and 59 died at the endpoint of fol-low-up.The median survival time of gastric cancer patients with SF3B4≥1.51 and miR-96≥1.28 was(23.7±5.4)months lower than that of SF3B4<1.51 or miR-96<1.28 patients(31.2±6.5)months(Log rank=11.457,P<0.001).Conclusion The expression of SF3B4 and miR-96 in gastric cancer patients undergoing gastroscopy biopsy is significantly increased,which is closely related to the severity,prognosis,and survival of the disease.It can be used as a biomarker for evaluating the condition and prognosis of gastric cancer,and the combined detection of the two can improve the sensitivity and specificity of predicting poor prognosis of gastric cancer.关键词
胃癌/剪接因子3b亚基4/微小RNA-96/病情/预后Key words
Gastric cancer/Splicing factor 3b subunit 4/Micro RNA-96/Disease condition/Prognosis分类
临床医学引用本文复制引用
董杰,杨松,肖俊,李鹏程..胃镜活检组织SF3B4及miR-96表达在胃癌病情及预后评估中的临床价值[J].疑难病杂志,2024,23(1):46-51,6.基金项目
湖北省自然科学基金项目(WJ2019AB008) Hubei Provincial Natural Science Foundation Project(WJ2019AB008) （WJ2019AB008）
